Gene Transfer Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MCK.GALGT2

Inclusion Criteria: * Nonambulant subjects, age 9 or older * Confirmed mutation in the DMD gene using a clinically accepted technique that completely defines the mutation * A magnetic resonance image of the EDB showing preservation of sufficient muscle mass to permit transfection * Males of any ethnic group will be eligible * Ability to cooperate with all study procedures * Willingness of sexually active subjects with reproductive capacity to practice reliable method of contraception (If appropriate). * Stable dose of corticosteroid therapy (including either prednisone or deflazacort and their generic forms) for 12 weeks prior to gene transfer Exclusion Criteria: * Active viral infection based on clinical observations. * The presence of a DMD mutation without weakness or loss of function * Symptoms or signs of cardiomyopathy, including: * Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs * Echocardiogram with ejection fraction below 40% * Serological evidence of HIV infection, or Hepatitis A, B or C infection * Diagnosis of (or ongoing treatment for) an autoimmune disease * Persistent leukopenia or leukocytosis (WBC ≤ 3.5 K/µL or ≥ 20.0 K/µL) or an absolute neutrophil count \< 1.5K/µL * Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer * Subjects with rAAVrh74 binding antibody titers ≥ 1:400 as determined by ELISA immunoassay * Presence of circulating anti-Sda antibodies as determined by study approved laboratory. * Abnormal laboratory values in the clinically significant range, based upon normal values in the Nationwide Children's Hospital Laboratory